FDA approves Belviq for treatment of obesity

Author(s):

On June 27, the U.S. Food and Drug Administration approved Belviq (lorcaserin hydrochloride) for the treatment of obesity. It is to be used in combination with a reduced-calorie diet and exercise for chronic weight management. The drug is approved for use in adults with a body mass index (BMI) of 30 or greater (obese), or adults with a BMI of 27 or greater (overweight) and who have at least one weight-related condition such as hypertension, type 2 diabetes, or dyslipidemia. Read more.

LEAVE A REPLY

Please enter your comment!
Please enter your name here